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Background: Menopause results in a lack of regular menstrual cycles, leading to the reduction of estrogen
production. On the other hand, ovarian androgen synthesis is still present at reduced levels and requires expression
of several steroidogenic enzymes.
Methods: This study was performed on 104 postmenopausal women hospitalized due to uterine leiomyomas,
endometriosis, and/or a prolapsed uterus. Patients were divided into three groups depending on the time from
menopause. Group A patients experienced menopause 1–5 years before enrollment in the study (42 women).
Group B included women who had their last menstruation 5–10 years before the study (40 women). Group C
consisted of 22 women who were more than 10 years past menopause. Hysterectomy or removal of the uterine
corpus with adnexa was performed during laparotomy. We evaluated the expression of aromatase cytochrome
P450 (CYP 19) and 17β-hydroxysteroid dehydrogenase (17β HSD) by employing immunohistochemistry.
Results: Activity of 17β-HSD and CYP19 was demonstrated in the cytoplasm of stromal cells of postmenopausal
ovaries, epithelium cells coating the ovaries, vascular endothelial cells, and epithelial inclusion cysts. However, overall
expression of both 17β-HSD and CYP 19 decreased with time after menopause.
Conclusion: Demonstration of the activity of the key enzymes of ovarian steroidogenesis, CYP 19 and 17β-HSD,
confirms steroidogenic activity in the ovaries of postmenopausal women. Nevertheless, ovarian steroidogenic activity
decreases with time, and its significant decrease occurs 10 years after menopause.
Keywords: Women’s ovaries, Menopause, Steroidogenesis, Aromatase cytochrome P450, 17β-hydroxysteroid
dehydrogenase, ImmunexpressionIntroduction
The key enzymes of ovarian steroidogenesis are hydrox-
ylases and oxidases, which belong to a large family of
cytochrome P450 [1-4] that consists of 480 enzymes,
including i) P450scc, which is responsible for cleaving
the side chain of cholesterol, ii) P450c11, which medi-
ates the conversion of 11-deoxycorticosterone to cortico-
sterone and possesses 11-hydroxylase, 18-hydroxylase,
and 19-methylooxydase activities, iii) P450c17, which medi-
ates 17-hydroxylation of pregnenolone and progesterone,* Correspondence: maria@laszczynska.pl
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article, unless otherwise stated.iv) P450c21, which has 21-hydroxylase activity, and v)
aromatase cytochrome P450, whose activity directs
aromatisation of androgens to estrogens [4-8]. Steroido-
genesis includes a few characteristic reactions such as i)
side-chain cleavage as a result of desmolase activity, ii)
conversion of hydroxyl groups to ketone groups mediated
by dehydrogenase, and iii) addition of hydroxyl groups
(hydroxylation) by a reaction involving the formation of
double bonds (removing hydrogen atoms) and saturation
(adding hydrogen atoms) [3,4].
The most important step in women’s steroidogenesis
is aromatisation of androgens, which leads to the gen-
eration of estrogens. This process is mediated by aromatasetral Ltd. This is an Open Access article distributed under the terms of the
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reticulum of granulosa cells in many steroidogenic and
non-steroidogenic tissues and glands, including the ovar-
ies, placenta, adipose tissue, hair, vascular smooth muscle,
skin, liver, bones (osteoblasts), and blood vessels [4-6,8,9].
The human gene encoding aromatase cytochrome P450
is located on the long arm of chromosome 15, region 21.2
(15q21.2) and is called CYP19. This name reflects enzym-
atic oxidation of the methyl group at C-19 [3,4,10]. In the
ovary, aromatase cytochrome P450 catalyzes conversion
of testosterone (T) to estradiol (E2), androstendione (A) to
estrone (E1), and 16α-hydroxylated dehydroepiandrosterone
(DHEA) to estriol (E3) [5,6,11]. In women of reproductive
age, 70% of the E1 and over 95% of the E2 circulating in
serum are ovary-derived [4,8]. The rest of the serum-
circulating estrogens come from peripheral conversion
of androgens, mainly due to conversion of androsten-
dione [5-7,11].
Unlike most of the enzymes involved in steroidogen-
esis, CYP 19 is expressed in target tissues with active
steroidogenesis (ovaries, placenta) as well as in other
non-steroidogenic tissues [11-13]. A number of studies
have confirmed a key role of CYP 19 in steroidogenesis,
especially in aromatisation of androgens to estrogens. Pa-
tients lacking this complex suffer from hypergonadotropic
hypogonadism [14-16]. On the other hand, aromatase in-
hibitors are the most suitable drugs for inhibiting estrogen
biosynthesis in some estrogen-sensitive diseases, such as
breast cancer, ovulation disorders, endometriosis, fibroids,
or precocious puberty [17-23].
The regulation of estrogen activity depends on oxidation
and reduction reactions mediated by isoforms of 17β-
hydroxysteroid dehydrogenase (17β-HSD), which catalyze
the conversion of less-active 17-keto steroids to more
potent 17β-hydroxy steroids, and many isoforms of this
enzyme have been identified, differing in expression
profiles, regulatory mechanisms, and substrates. The
scheme of ovarian steroidogenesis is presented in Figure 1
[1,2,7,8,24-30].
Due to the recently widely discussed existence of
postmenopausal ovarian steroidogenic activity and the
influence of the ovaries on women’s postmenopausal
life quality and overall life span we evaluated the
immunoexpression of two key ovarian enzymes regulating
steroidogenesis: CYP 19 and 17β-HSD in the ovaries of
postmenopausal women. These observations are also es-
sential for pre- and postmenopausal women with benign
ovarian tumors to facilitate decision if the oophorectomy
is necessary.
This study extends our previous work on the morpho-
logical structure of the postmenopausal ovary [31,32] and
immunoexpression of the androgen, estrogen, and proges-
terone receptors [33,34] and the follicle stimulating and
luteinizing hormone receptors [35].Methods
Study group
The study group consisted of 104 postmenopausal women
hospitalized due to uterine leiomyomas, endometriosis,
and/or a prolapsed uterus between 2003 and 2008 at the
Department of Reproduction and Urogynecology at the
Pomeranian Medical University in Szczecin. All women
subjects met the inclusion criteria and didn’t meet the ex-
clusion criteria. The inclusion criteria were: i) 12 or more
months since the last menstruation, ii) no postmenopausal
hormonal therapy, iii) normal PAP smear and mammog-
raphy, iv) normal blood pressure, v) no history of surgeries
that could affect blood flow to the ovaries, and vi) no
history of cancer or endocrine disorders such as thyroid
disease or diabetes. The research plan was approved by
the Bioethics Commission of the Pomeranian Medical
University, and the research was supported by grant No. 2
PO5E-10527 from the Polish State Committee for Scien-
tific Research.
Patients who met the inclusion criteria were divided
into three groups (A, B, and C), depending on the time
from menopause. Group A patients experienced meno-
pause 1–5 years before being qualified for the study
(42 women). Group B included women who had their
last menstruation 5–10 years before the study (40 women).
Group C consisted of 22 women who were at least 10 years
post menopause. For ethical reasons, a control group was
not studied.
Immunohistochemistry (IHC)
Hysterectomy or removal of the uterine corpus with
adnexa was performed during laparotomy and the “wedge
shape” samples of ovaries were obtained for histological
analysis. To determine the expression of aromatase
cytochrome P450 and 17β-HSD by IHC, samples were
preserved in 4% buffered formalin solution and embed-
ded in paraffin. Histological sections were placed in
the pH 9.0 buffer and then boiled for 30 minutes in a
water bath at 99°C. All sections were then incubated
for 24 hours at 4°C in a humid chamber with MCA
2077S primary antibody (Serotec, USA) to detect CYP
19 and with HPA015307 primary antibody (Sigma, USA)
to detect 17β-HSD.
For anti-aromatase antibody detection, the ABC Staining
System (Santa Cruz Biotechnology, USA) was used, while
for anti-17β-HSD primary antibody detection, labeled
polymer from the Dako Real EnVision Detection System
(Dako, Denmark) was used. In both cases, to visualize
the immunohistochemical reaction, 3,3’diaminobenzidine
(DAB) was used. In the last step, sections were counter-
stained with Meyer’s hematoxylin. For the negative con-
trol, specific antibodies were omitted in the staining
procedure. The slides were examined by employing light
microscope (Olympus BX41).
Figure 1 Scheme of ovarian steroidogenesis.
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17β-HSD (Figure 2) and CYP 19 (Figure 3) activity were
detected in the cytoplasm of stromal cells of postmeno-
pausal ovaries, epithelium cells coating the ovaries, vascular
endothelial cells, and in epithelial inclusion cysts.
In group A, a strong intensity of both activities was
demonstrated in epithelial inclusion cysts, epithelial cells
coating the ovaries, and in the cytoplasm of stromal cells.
The intensity of both reactions was strong and/or semi
strong in vascular endothelial cells.
In group B, strong immunoexpression of 17β-HSD
was demonstrated in epithelial inclusion cysts and semi
strong in ovarian stromal cells. Semi strong reaction was
also observed in vascular endothelial cells, and in epithe-
lium cells of the ovary. In the same group, semi strong or
weak immunoexpression of CYP 19, was demonstrated in
ovarian stromal cells, a semi strong reaction was observed
in vascular endothelial cells, and epithelial inclusion cysts,
while in and epithelium cells coating the ovary, the reac-
tion was strong.
In group C, the immunoexpression of 17β-HSD and
CYP 19, in all studied ovarian structures (i.e., stromal cells
of the postmenopausal ovaries, epithelium cells coating
the ovaries, vascular endothelial cells and epithelial inclu-
sion cysts) was weak or weak and semi strong in vascular
endothelial cells.
We observed that immunoexpression of both 17β-HSD
and CYP 19 decreased with time after menopause (Tables 1
and 2).
Discussion
The results presented here are the first concerning
the immunoexpression of CYP 19 and17β-HSD in the
human ovary of postmenopausal women. Our studiesdemonstrated CYP 19 and 17β-HSD expression in the
ovarian surface epithelial cells, inclusion cysts, vascular
endothelial cells, and stromal cells. The intensity of re-
action decreased significantly with time after the last
menstruation. The activity of key enzymes involved in
gonadal steroidogenesis, such as 17β-HSD and CYP
19, provides strong evidence for the presence of the
steroid biosynthesis in the postmenopausal ovaries.
These results also indicate a reduction in the activity of
gonadal steroidogenesis as a function of time elapsed
from menopause. Thus, our results confirm the presence
of relatively high concentrations of steroids in ovarian tis-
sue homogenates and their reduction in postmenopausal
women, especially in women 10 years after the last
menstruation [8,12].
The activity of key ovarian steroidogenesis enzymes in
postmenopausal women are estimated with different
methods, because the ovarian stromal cells represent a
heterogeneous collection of cells [36-38].
The presence of enzymes of the aromatase cytochrome
group was detected employing immunohistochemistry in
the ovaries of postmenopausal women for the first time
by Inkster and Brodie in 1991 [19]. On the other hand,
the activities of different types of 17β-HSD have been
found in many of the human tissues examined, the highest
estrogenic activity of 17β- HSD was found in ovary, endo-
metrium, prostate, testis, placenta, liver, and adipose tissue
[19]. In 2006 Havelock et al. showed that all enzymes ne-
cessary for androgen synthesis are present in the ovaries
of postmenopausal women [19]. In their study, using the
QRT method, the presence of CYP 19 and 17β-HSD and
decreased activity of 3β-HSD were detected. Additionally,
as reported for the ovaries of postmenopausal women, the
delta-5 pathway of steroidogenesis is favored, which leads
Figure 2 An ovary of a patient from group A (<5 years after menopause). Strong cytoplasmic reaction of 17β-HSD in the surface epithelium
(arrow), in the cyst epithelium (arrow) (A), in the ovarian stromal cells (arrowhead), and semi strong reaction in the vascular endothelial cells
(arrow) (B). An ovary from a patient from group B (5–10 years after menopause). Strong cytoplasmicreaction of 17β-HSD in the cyst epithelium
(arrow) and semi strong in ovarian stromal cells (arrowhead) (C). An ovary of a patient from group C (>10 years after menopause). Semi strong
cytoplasmic expression of 17β- HSD in the vascular endothelial cells (arrow) and weak expression in the ovarian stromal cells (D). SC, stromal cells;
LC, lumen cyst; LV, lumen vessel. Inserts in panels A, C and D) show negative controls. Magnification, x330.
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peripherally converted to testosterone, dihydrotestoster-
one, androstendione, and estrogens [19]. However, in this
latter study, no tissue localization of enzymes involved in
this process has been demonstrated.
Our current study demonstrates localization of two
key enzymes involved in the steroidogenic biosynthesis
pathway, CYP 19 and 17β-HSD, in postmenopausal
ovaries, which indicates that the postmenopausal ovary
acts as an important contributor to the synthesis of
steroids destined for peripheral metabolism.
Studies on the pathogenesis of diseases of the peri-
menopausal period identified aromatase activity not only
in gonadal tissues but also in adipose tissue, muscles,
mammary gland, and liver [39-41]. Moreover, the activity
of aromatase located in tissues other than gonad is notFSH-dependent [4,8,39,41-44]. Therefore, the application
of aromatase inhibitors in women results in a significant
reduction in estrogen synthesis [39,41], as seen, for ex-
ample, in women with breast cancer, where the conversion
of androgens to estrogens takes place directly in the tumor
cells [39,45,46].
Different types of 17β-HSD use various substrates. The
most active type, 17β-HSD1, is highly complementary to
estrogenic substrates, especially E1, which is converted in
the gonads and many peripheral tissues to E2. In trans-
genic mice, increased activity of 17β-HSD1 in the presence
of E1 substrate leads to increased estrogen-dependent
tumor growth. This was confirmed by administration of
17β-HSD1 inhibitor, which significantly reduced growth of
this estrogen-dependent tumor [26]. The presence of 17β-
HSD in the postmenopausal ovary suggests steroidogenic
Table 1 Immunoexpression of 17β-HSD in the ovaries of













Group A +++ +++ +++/++ +++
(n = 42)
Group B ++ +++ ++ ++
(n = 40)
Group C + + ++/+ +
(n = 22)
(+++) strong reaction, (++) semi strong reaction, (+) weak reaction.
Table 2 Immunoexpression of aromatase cytochrome
P450 in the ovaries of postmenopausal women,












Group A +++ +++ +++/++ +++/++
(n = 42)
Group B +++ ++ ++ ++/+
(n = 40)
Group C + + ++/+ +
(n = 22)
(+++) strong reaction, (++) semi strong reaction, (+) weak reaction.
Figure 3 An ovary of a patient from group A (<5 years after menopause). Strong cytoplasmic reaction of CYP 19 the cyst epithelium
(arrow), and semi strong in the ovarian stromal cells (arrowhead) (A). An ovary of a patient from group B (5–10 years after menopause). Strong
cytoplasmic reaction of CYP 19 in the surface epithelium (arrow) and weak in ovarian stromal cells (arrowhead) (B). An ovary of a patient from
group C (>10 years after menopause). Cytoplasmic expression of CYP 19 in the vascular endothelial cells (arrow) (C). SC, stromal cells; LC, lumen
cyst; LV, lumen vessel. Inserts in panels A, B and C show negative controls. Magnification, x 660.
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the only source of estrogens in women. 17β-HSD is also
involved in peripheral E2 formation, despite the fact that
its expression in peripheral tissues is low [47].
A few studies demonstrated that genetic polymorphism
of the steroidogenic enzymes in postmenopausal women’s
ovaries cause dysfunction and may be a cause of increased
risk of endometrial and breast cancers. Postmenopausal
women with specific CYP19 genetic polymorphisms are at
increased risk of breast cancer, and there were higher
CYP19 and 17β-HSD activities in tumor cells than in nor-
mal cells. Moreover, CYP 19 activity was higher in women
with breast and endometrial cancers than in healthy
women [48-50], and 17β-HSD activity was higher in
breast cancer patients [51-53]. Undoubtedly, research
on key gonadal and extragonadal steroidogenesis enzymes
and their genetic polymorphisms should be continued,
because given the nature of the postmenopausal period, it
is very difficult to demonstrate a positive impact of the
gonads on life quality, survival, and cancer risk in women
of that age.
On the one hand, it is known that postmenopausal
women with preserved gonads have longer survival, higher
life quality, and less-frequent cardiovascular complications,
dementing illnesses, and osteoporotic complications. On
the other hand, the presence of gonads increases the risk
of ovarian and breast cancer. The U.S. data show that the
proportion of deaths from cardiovascular diseases in post-
menopausal women is much higher than from cancer,
which is confirmed by data from the Central Statistical
Office in Poland for the years 2009–2010. Our own data
and data from the published literature also indicate that
gonadal steroidogenic activity clearly decreases after
10 years from menopause, and in this period, preventive
bilateral ovariectomy does not affect life quality and sur-
vival time but significantly reduces the risk of cancer.Conclusions
Our data support the conclusion that steroidogenesis, as
evidenced by activities of the key ovarian steroidogenic
enzymes, CYP 19 and 17β-HSD, is still active in the ovaries
of postmenopausal women. This process decreases grad-
ually after menopause and is significantly reduced after
10 years from the last menstruation. Therefore taking into
consideration hormonal activity in postmenopausal ovaries,
prophylactic, bilateral ovariectomy can be safely recom-
mended in the first 10 years after the last menstruation.
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